Bone Voyage! Biocon Biologics Lands EU Approval for Denosumab Twins

Unknown Apr 02, 2026 1,150 Views

Biocon Biologics Limited, a Biocon Limited subsidiary, has secured European Commission marketing approval for two Denosumab biosimilars, Vevzuo® and Evfraxy®, a major milestone in its expansion in bone health therapeutic drugs in the European Union. The clearances follow a...